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Objective: To derive a US-based value set for the EQ-5D-5L questionnaire using an international, standardized protocol
developed by the EuroQol Group.
Methods: Respondents from the US adult population were quota-sampled on the basis of age, sex, ethnicity, and race. Trained
interviewers guided participants in completing composite time trade-off (cTTO) and discrete choice experiment (DCE) tasks
using the EuroQol Valuation Technology software and routine quality control measures. Data were modeled using a Tobit
model for cTTO data, a mixed logit model for DCE data, and a hybrid model that combined cTTO and DCE data. Model
performance was compared on the basis of logical ordering of coefﬁcients, statistical signiﬁcance, parsimony, and
theoretical considerations.
Results: Of 1134 respondents, 1062, 1099, and 1102 respondents provided useable cTTO, DCE, and cTTO or DCE responses,
respectively, on the basis of quality control criteria and interviewer judgment. Respondent demographic characteristics and
health status were similar to the 2015 US Census. The Tobit model was selected as the preferred model to generate the value
set. Values ranged from20.573 (55 555) to 1 (11111), with 20% of all predicted health states scores less than 0 (ie, worse than
dead).
Conclusions: A societal value set for the EQ-5D-5L was developed that can be used for economic evaluations and decision
making in US health systems. The internationally established, standardized protocol used to develop this US-based value
set was recommended by the EuroQol Group and can facilitate cross-country comparisons.
Keywords: cost-utility analysis, EQ-5D, quality-adjusted life-year, stated preference, United States, utility, value.
VALUE HEALTH. 2019; 22(8):931–941Introduction
The EQ-5D is a measure of health that has been widely used
around the world to inform resource allocation and decision
making in healthcare.1 The EQ-5D-3L, which has 3 levels for each
of the 5 dimensions of health, was revised and expanded to 5
levels as the EQ-5D-5L.2 The EQ-5D-5L has shown improved
measurement properties, including greater discrimination among
known groups and reduced ceiling effects compared with the EQ-
5D-3L.3–5ss correspondence to: A. Simon Pickard, PhD, Department of Pharmacy Syste
th Wood St, MC 871, Chicago, IL 60612, USA. Email: pickard1@uic.edu
15 - see front matter Copyright ª 2019, ISPOR–The Professional Society for
cess article under the CC BY-NC-ND license (http://creativecommons.org/lic
doi.org/10.1016/j.jval.2019.02.009In the United States, there is renewed interest in value
frameworks that focus on the trade-offs between potential bene-
ﬁts and harms of treatment.6–9 Despite legislation against it as a
consideration in federal payer reimbursement decisions,10 cost per
quality-adjusted life-year (QALY) continues to be an important
metric for evaluating the value of healthcare interventions in the
United States,8,11,12 and the EQ-5D features prominently as a
preference-based measure of health for such evaluations.13
Much of the literature on cost-utility analysis in the United
States draws from the EQ-5D-3L value set.14 Upon publication ofms, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago,
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
enses/by-nc-nd/4.0/).
932 VALUE IN HEALTH AUGUST 2019the EQ-5D-5L descriptive system, an interim crosswalk was
developed to facilitate the generation of preference-based sum-
mary scores on the basis of EQ-5D-5L responses.15 The EuroQol
Group invested in a scientiﬁc program that examined alternative
approaches to preference elicitation,16,17 developed methods to
improve data quality,18 and demonstrated the robustness of these
approaches across countries and languages.19 The accumulation of
evidence supported a standardized valuation protocol imple-
mented in software named the EuroQol Valuation Technology
(EQ-VT).20,21 The EQ-VT has been reﬁned in several developmental
phases and is recommended by the EuroQol Research Foundation,
a not-for-proﬁt research foundation whose membership consists
of international, multidisciplinary researchers21–23 for conduct of
EQ-5D-5L valuation studies.24–28 The EQ-VT has been shown to
improve data quality and minimize interviewer effects.18,29
Building on this evidence to apply a standardized approach to a
national value set, the aim of this study was to estimate a value set
for the EQ-5D-5L that will support economic evaluation of
healthcare interventions in the United States; by using an inter-
nationally established protocol, the US value set will also facilitate
cross-country comparisons.Methods
Study Design
The research design and data collection followed a research
program developed by the EuroQol Group. The study protocol was
approved by the institutional review board at the University of
Illinois at Chicago (IRB#2017-0289). We followed the CREATE
checklist for reporting key elements of valuation studies for
multiattribute utility instruments.30
Descriptive System
Health states were described using the EQ-5D-5L, which in-
cludes 5 dimensions of health (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression). Each dimension de-
scribes 5 levels of problems: “no,” “slight,” “moderate,” “severe,”
and “extreme” problems (or “unable to”).2 Each of the 3125 (55)
health state proﬁles described by the EQ-5D-5L can be repre-
sented by a 5-digit number that ranges from 11111 (no problems
in any dimension) to 55 555 (extreme problems or unable to in all
dimensions). A “misery score” can be calculated by summing all
the digits of the proﬁle to broadly categorize health states by
overall severity and is not a substitute for a preference-based
score.
Preference Elicitation Methods
Both composite time trade-off (cTTO) and discrete choice
experiment (DCE) methods were used in the valuation protocol.
The cTTO method22,31–33 compared a suboptimal EQ-5D-5L health
state to full health, using the conventional TTO to elicit “better-
than-dead” values and the lead-time TTO to elicit “worse-than-
dead” (WTD) values (see Appendix A in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2019.02.009). If the respon-
dent indicated that a health state was WTD, an additional 10 years
of time (lead time) was granted to elicit WTD values; thus, the
most negative elicited cTTO value was 21. The smallest unit of
time traded was 6 months. Full health and death were used as
anchors in the cTTO tasks. DCE tasks asked respondents to state
their preference between 2 different EQ-5D-5L health state pro-
ﬁles in a pairwise comparison (see Appendix B in SupplementalMaterials found at https://doi.org/10.1016/j.jval.2019.02.009). Opt-
out options (eg, “neither”) were not provided.
Health State Selection
The experimental design was informed by multinational EQ-
5D-5L cTTO and DCE pilot studies, which included US data.20,22
For the cTTO tasks, 86 EQ-5D-5L health states were selected to
represent a wide range of health problems.20 Health states were
grouped into 10 blocks with 10 health states per block. All 10
blocks contained the worst possible health state (55555), 1 mild
state (mild problems in 1 dimension only), and 8 health states
unique to each block that varied in severity. For the DCE tasks, 196
paired comparisons constituted the experimental design.20,22 Ten
of the 196 pairs consisted of very mild health state pairs and the
rest were drawn to produce a D-error minimized design.20 These
paired comparisons were subdivided into 28 blocks of 7 choice
sets.
Sampling and Recruitment
Data were collected between May and September 2017 from 6
US metropolitan areas (Chicago, Philadelphia, Seattle, Birming-
ham, Phoenix, and Denver). Locations were chosen to ensure
representativeness of the US population and sampling in all
census regions.34–36
Noninstitutionalized English- and Spanish-speaking adult
members of the US general population were eligible to partici-
pate. The inclusion criteria were as follows: (1) 18 years of age or
older; (2) current US residency; (3) ability to understand the
tasks, as judged by interviewer; (4) ability to provide informed
consent; and (5) ability to complete the tasks in English or
Spanish. Quota sampling was based on age, sex, ethnicity, and
race to obtain a sample representative of the US general
population.
Three recruitment strategies were used. First, ResearchMatch,
a national, web-based recruitment tool (https://www.researc
hmatch.org), was used to contact potential respondents who
lived near the recruitment areas. Second, the International Society
of Pharmacoeconomics and Outcomes Research student chapters
near recruitment sites were contacted to promote study aware-
ness. Third, community platforms (eg, public ﬂyers, online plat-
forms, and community centers) were used to generate local
interest.
During data collection at a given location, the study team
continued to recruit participants. This multipronged approach to
recruitment was guided by recent valuation study experiences and
adapted to the US context.37 Interviews were scheduled
throughout each metropolitan area, and respondents were given
$30 as cash incentive for study participation.
Survey Administration
All surveys were completed through interviewer-assisted data
collection using laptops with the latest version of the EQ-VT
software,19 version 2.0, in Spanish or English. To maintain con-
sistency, the same interviewers were involved throughout data
collection. All interactions followed the same format. First, par-
ticipants were given study information, and verbal informed
consent was obtained. Second, participants reported their current
level of health as described by the EQ-5D-5L and rated their health
using the EuroQol visual analogue scale.38 Third, respondents
completed valuations using the cTTO method. Respondents began
with 5 practice cTTO exercises. Respondents then valued 10 EQ-
5D-5L health states, presented in random order. Afterwards, a
feedback module was completed, where all 10 EQ-5D-5L health
PREFERENCE-BASED ASSESSMENTS 933states were presented in rank order on the basis of respondent-
assigned cTTO values. Respondents ﬂagged any health states
that were “out of order” to ensure the unﬂagged responses
accurately reﬂected their health preferences. Flagged health states
could not be revalued.
Next, respondents completed 7 DCE tasks, presented in
random order. The left/right display of the health state pairs was
randomized at the respondent level to avoid framing effects. For
all preference tasks, respondents read each health state descrip-
tion aloud and were encouraged to think aloud to ensure
engagement and help interviewers assess comprehension. Finally,
respondents completed sociodemographic and health-related
questions.
Interviewer Training, Role of Interviewer, and Quality
Control Process
All interviewers were trained by EuroQol scientiﬁc staff us-
ing EQ-VT 2.0.19 Interviewers were trained to instruct, motivate,
and probe respondents for understanding of valuation tasks.
During data collection, quality control reports were reviewed
daily to ensure cTTO data quality on the basis of several
criteria22: (1) the interviewer used at least 3 minutes to explain
the ﬁrst practice cTTO task; (2) the interviewer demonstrated
WTD task (ie, lead-time portion of cTTO) for the ﬁrst or
second practice cTTO task; (3) the respondent avoided assign-
ing the worst health state (55 555) a cTTO value of 0.5 or more
points higher than values assigned to other health states; and
(4) the respondent used at least 5 minutes to complete all 10
EQ-5D-5L cTTO tasks. Interviews that did not meet all 4 criteria
were discussed during quality control debrieﬁngs. These in-
terviews were not necessarily excluded from analysis if the
respondent demonstrated comprehension of the preference
tasks.
Data Analysis and Modeling of EQ-5D-5L Health States
A Tobit model for cTTO data (model 1), a mixed logit model
for DCE data rescaled to the health utility scale (model 2), and a
hybrid model that combined cTTO and DCE data (model 3) were
used to model health state preferences. The dependent variables
for the Tobit and mixed logit models were cTTO values and the
DCE stated choice (ie, A or B for each given health state pair),
respectively. If the respondent did not comprehend the choice
task(s), then the respondent’s preference data (cTTO and/or
DCE) were excluded from the respective analysis. Respondent-
ﬂagged cTTO responses were excluded from the base-case
analysis.
Model 1 (Tobit) estimated utility decrements for each
parameter. Observed cTTO values were regressed onto 19 total
parameters, that is, 4 dummy variables for each health dimen-
sion representing the disutility from level 1 (no problems), the
referent category, except for usual activities levels 4 and 5,
which were constrained to have the same utility decrement; the
model also contained a random effect to account for dependency
of repeated observations within respondents (Equation 1).
Model 1 left-censored the cTTO data at 21, because respondents
could hypothetically continue trading beyond the left bound
at 21 for WTD values. Censoring at 1, that is, right-censoring,
was not pursued because 1 is the theoretical upper bound in
health utilities, and the EQ-5D-5L health states were valued
against full health on the cTTO. Tobit models assume that a
latent variable (cTTO*) underlies the observed cTTO values and
uses a likelihood function to adjust the parameter estimates forthe probability of the cTTO* value beyond the censored value (ie,
,21) (Equation 2).
cTTOij ¼ mj1ui1 εij
mj ¼ 11 b1MO2j1b2MO3j1b3MO4j1b4MO5j1
1 b5SC2j1 b6SC3j1 b7SC4j1 b8SC5j1
1 b9UA2j1 b10UA3j1 b11

UA4j1UA5j

1
1 b12PD2j1 b13PD3j1 b14PD4j1b15PD5j1
1 b16AD2j1 b17AD3j1 b18AD4j1 b19AD5j
uiwiid N

0;s2u

is a subject­level random intercept
εijwiid N

0;s2j

is a heteroscedastic error term
(1)
where MO is mobility, SC is self-care, UA is usual activities, PD is
pain/discomfort, and AD is anxiety/depression; the number
following the dimension indicates level of severity (eg, MO2 is
mobility level 2); iid is independent and identically distributed; i
is the respondent; and j accounts for the multiple tasks
completed.
cTTO ¼

cTTOif cTTO >21
21 if cTTO#21
(2)
Furthermore, as the observed variance of the cTTO values
increased with increasing severity of the health state, we investi-
gated several methods of modeling the heteroscedasticity of the
error term, such as log link with polynomials of mj up to the fourth
degree and a log link with 21 dummy variables corresponding to
each dimension level of the EQ-5D-5L and a constant. We chose
the most appropriate model (fourth-degree mj polynomial)
considering Akaike information criterion, Bayesian information
criterion, and estimation stability (Equation 3).
sj ¼ exp

g01g1mj1g2m
2
j 1g3m
3
j 1g4m
4
j

(3)
Model 2 used a mixed logit, that is, random parameter logit
that can account for repeated observations, to model the DCE data.
The model included regression coefﬁcients and random effects for
each of the 20 dummy variables, reﬂecting utility decrements
associated with levels 2, 3, 4, and 5 for each of the 5 domains
(Equation 4).
Uit ¼b1iðMO2Þj1b2iðMO3Þj1b3iðMO4Þj1b4iðMO5Þj1b5iðSC2Þj
1b6iðSC3Þj1b7iðSC4Þj1b8iðSC5Þj1b9iðUA2Þj1b10iðUA3Þj
1b11iðUA4Þj1b12iðUA5Þj1b13iðPD2Þj1b14iðPD3Þj
1b15iðPD4Þj1b16iðPD5Þj1b17iðAD2Þj1b18iðAD3Þj
1b19iðAD4Þj1b20iðAD5Þj1εit
(4)
where i is the respondent, t is the choice alternative in choice sets,
Uit represents latent utility, bki w N(bk, sbj2) are random effects,
and εit is the residual termwith an extreme value distribution. The
model estimates obtained using DCE are on a latent utility scale,
and consequently cannot be used independently as the basis for
generating a value set on a cardinal scale. Therefore, mixed logit
(model 2; Table 2) coefﬁcients were transformed to a 1 (11111) to
0 (dead) scale using a rescaling parameter obtained from a line ﬁt
to the scatterplot of cTTO censored means and DCE mixed logit
latent health values, assuming a linear relationship39,40 (see
Appendix F in Supplemental Materials found at https://doi.org/1
0.1016/j.jval.2019.02.009).
Finally, model 3 used a hybrid approach. The hybrid approach
added the log-likelihood functions of Tobit (cTTO; model 4) and
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log-likelihood function with heteroscedasticity of the variance
(Equations 5 and 6).
Log likelihood ¼ 21
2
X
j˛C0
(
Log

2ps2j

1

yj2xb
sj
2)
1
X
j˛L0
Log

F

212xb
sj

1
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j˛D
2yj3Log

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1

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3Log
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
(5)sj ¼ exp

g1MO2j1g2MO3j1g3MO4j1g4MO5j1g5SC2j1g6SC3j1g7SC4j1g8SC5j1g9UA2j1g10UA3j1g11UA4j
1 g12UA5j 1 g13PD2j 1 g14PD3j 1 g15PD4j 1 g16PD5j 1 g17AD2j 1 g18AD3j 1 g19AD4j 1 g20AD5jÞ
(6)where yj is the dependent variable, C0 represents cTTO responses
greater than 21, L0 represents TTO responses equal to 21, and xA
and xB represent the attributes of alternatives A and B in the
paired DCE comparisons.39,40
The component models of the hybrid model were Tobit for
cTTO (model 4; heteroscedasticity allowance, censoring at 21)
and conditional logit for DCE (model 5), neither of which could
account for repeated measures within a respondent (see
Appendix G in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2019.02.009); several approaches were
used to assess whether the cTTO and DCE as modeled by the
component models were compatible and therefore combinable
for the hybrid model. A Bland-Altman plot was developed to
examine the difference and mean for the predicted cTTO
and DCE values (see Appendix H in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2019.02.009). Predicted
health state values from the hybrid model and its component
models were plotted, and Pearson correlation, Spearman cor-
relation, and Lin concordance coefﬁcients were also
calculated to assess model compatibility (see Appendix I in
Supplemental Materials found at https://doi.org/10.1016/j.jval.2
019.02.009).
Logical ordering of parameter estimates (ie, larger utility
decrements with more severe problems), statistical signiﬁcance
of the parameters (P,.050), model parsimony, and theoretical
considerations related to model speciﬁcations (eg, handling of
censored values, accounting for panel data, and hetero-
scedasticity assumptions) were all considered in model selec-
tion. Kernel density distributions were plotted for the preferred
US EQ-5D-5L value set, the US EQ-5D-3L value set,14 and the
crosswalk developed by van Hout et al15 to show the distribu-
tional properties of each scoring algorithm (eg, skewness, mo-
dality, and range of scale). Finally, sensitivity analyses were
performed to evaluate the robustness of the primary analysis:
(1) re-inclusion of respondent-ﬂagged cTTO responses, (2)
re-inclusion of preference data from all respondents, and (3)
examination of interviewer effects. Statistical analyses were
performed using SAS version 9.4 (SAS Institute, Chapel Hill, NC)
and STATA version 14.2 (StataCorp, College Station, TX). No
missing preference data were noted.Results
In total,1134 interviewswere conducted fromMay toSeptember
2017. Mean interview time was 58.3 6 71.1 minutes. Thirty-two
respondents (2.8%) did not comprehend the cTTO nor DCE tasks
per interviewer assessment, and all valuation data from these re-
spondentswere excluded from the primary analysis (Fig.1). The full
and analytic samples were generally representative of the US adult
population with respect to age, sex, race, ethnicity, prevalence of
chronic conditions, and general health status (Table 1).41–45 Char-
acteristics of respondents excluded from cTTO- and DCE-only
models are provided in Appendix C in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2019.02.009.cTTO and Discrete Choice Data
For the EQ-5D-5L cTTO tasks, data from 72 respondents were
excluded per interviewer assessment, resulting in 1062 re-
spondents providing 10 620 cTTO responses (Fig. 1). Respondents
ﬂagged 1234 cTTO responses (11.6%) using the feedback module.
Respondents took an average of 6.8 6 4.7 iterative steps before
they reached their point of indifference in cTTO tasks. The
observed mean cTTO values ranged from 20.366 for health state
55555 to 0.965 for health state 11121 (see Appendix D in Sup-
plemental Materials found at https://doi.org/10.1016/j.jval.2019.
02.009). A total of 324 (30.5%) respondents had at least 1 incon-
sistency; that is, health state A dominated health state B across all
dimensions, but A was assigned a lower cTTO value; 123 re-
spondents (11.6%) had an inconsistency involving 55555. After the
feedback module, 172 (16.2%) respondents provided an inconsis-
tent response (33 respondents [3.11%] involving 55555). Overall,
5.6% of all eligible cTTO responses were inconsistent, and incon-
sistency prevalence was reduced to 2.2% after the feedback
module.
The main analysis included all unﬂagged cTTO valuations (10
620 2 1234 = 9386 responses) from respondents who compre-
hended the task per interviewer assessment. Of these, 2251
(24.0%) cTTO responses were considered WTD (Fig. 2A). The pro-
portion of values clustered at 1, 0, and 21 was 20.5%, 5.1%, and
14.7%, respectively. Lower mean cTTO values and larger standard
deviations were observed as the health state misery score
increased (Fig. 2B).
For the DCE tasks, 1099 respondents were included in the DCE-
only model; that is, 35 respondents did not understand the DCE.
As the difference in overall severity between the 2 states
increased, respondents were more likely to choose the state with
the lower severity (see Appendix E in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2019.02.009).
Modeling EQ-5D-5L Health States
Model 2 had 2 disordered parameters, whereas models 1
and 3 had no disordering (Table 2). Coefﬁcients for model 2
were rescaled using the slope of the line ﬁt to the censored
cTTO disutility means and the mixed logit DCE latent values
Figure 1. Respondents included in the US EQ-5D-5L valuation study and responses retained.
Completed interviews
(n=1,134)
Respondents who did not
understand DCE and cTTO
(n=32)
Respondents who did not
  understand DCE only
(n=3)
Respondents who did
not understand cTTO only
(n=40)
Respondents who
understood cTTO 
(n=1,062)
cTTO responses
(n=10,620)
cTTO responses flagged
by respondent during
feedback module
(n=1,234)
cTTO responses
included
(n=9,386)
Respondents who
understood DCE 
(n=1,099)
DCE responses included
(n=7,693)
Tobit model: Respondents
who understood cTTO
(n=1,062)
Hybrid model: Respondents who
understood DCE and/or cTTO
(n=1,102)
Mixed logit model: Respondents
who understood DCE 
(n=1,099)
cTTO indicates composite time trade-off; DCE, discrete choice experiment; EQ-5D-5L, 5-level EuroQol 5-dimensional questionnaire.
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signiﬁcantly different from 0 (P,.0001). Dimension ranking in
terms of relative importance differed slightly across the 3
models. For the mixed logit (model 2) and hybrid (model 3)
models, the relative importance was as follows: pain/discomfort
(most important), anxiety/depression, mobility, self-care, and
usual activities (least important). For the Tobit TTO model
(model 1), mobility was marginally more important than anx-
iety/depression (0.322 and 0.321, respectively). The hybrid
model was in agreement with the cTTO and DCE as modeled byits component models (models 4 and 5; see Appendix G in
Supplemental Materials).
Preferred Model and Value Set
The Tobit cTTO model was selected as the preferred model on
the basis of its performance with respect to statistical signiﬁcance
of the estimates, ability to handle left-censored cTTO data, account
for panel data, and heteroscedasticity (Table 2). The largest utility
decrement for a dimension level was pain/discomfort level 5
Table 1. Respondent characteristics.
Characteristic General population* (%) Full sample (n = 1134) Analytic sample† (n = 1102)
Age (y), mean 6 SD 46.9 6 18.1 46.7 6 18.1
Age group (y), n (%)
18-34 30.5 358 (31.6) 354 (32.1)
35-54 34.5 394 (34.7) 381 (34.6)
>55 34.6 382 (33.7) 367 (33.3)
Range – 18-99 18-99
Sex, n (%)
Male 48.3 564 (49.7) 544 (49.3)
Female 51.4 565 (49.8) 553 (50.2)
Other46 0.3 5 (0.4) 5 (0.4)
Race, n (%)
White 65.5 685 (60.4) 679 (61.6)
Black 11.9 152 (13.4) 144 (13.1)
Asian or Paciﬁc Islander 5.3 79 (7.0) 74 (6.7)
American Indian/Alaskan Native 0.5 29 (2.6) 27 (2.5)
Hispanic ethnicity, n (%) 15.0 208 (18.3) 197 (17.9)
Education level greater than secondary, n (%) 58.9 732 (64.6) 718 (65.2)
Marital status, n (%)
Not married 48.0 556 (49.0) 537 (48.7)
Married or common-law – 322 (28.4) 317 (28.8)
Separated or divorced – 180 (15.9) 174 (15.8)
Widowed – 75 (6.6) 73 (6.6)
Child dependents, n (%)
None 71.2 916 (80.8) 888 (80.6)
Child(ren), #5 y old – 68 (6.0) 68 (6.2)
Child(ren), 6-17 y old – 180 (15.9) 176 (16.0)
Primary health insurance,47 n (%)
None 9 98 (8.6) 93 (8.4)
Public 36 480 (42.3) 458 (41.6)
Private 56 555 (49.1) 550 (50.0)
Location, n (%)
Midwest 21.3 358 (31.6) 346 (31.4)
Northeast 17.6 129 (11.4) 125 (11.3)
South 37.6 353 (31.1) 346 (31.4)
West 23.6 294 (25.9) 285 (25.9)
Country of birth, United States, n (%) 983 (86.7) 960 (87.1)
History of illness,45 n (%)
Hypertension 32.0 270 (23.8) 258 (23.4)
Arthritis 22.7 267 (23.5) 258 (23.4)
Diabetes 9.4 111 (9.8) 104 (9.4)
Heart failure 2.2 20 (1.8) 18 (1.6)
Stroke 1.8-2.4 23 (2.0) 22 (2.0)
Bronchitis 3.6 29 (2.6) 25 (2.3)
Asthma 7.5 132 (11.6) 130 (11.8)
Depression 25.7 295 (26.0) 285 (25.9)
Migraine 16.0 164 (14.5) 159 (14.4)
Cancer 5.9 65 (5.7) 64 (5.8)
None – 372 (32.8) 364 (33.3)
Health status,44 n (%)
Excellent/very good/good 85.6 980 (86.4) 955 (86.7)
Fair/poor 14.4 154 (13.5) 146 (13.3)
Self-reported EQ-VAS
Mean 6 SD 80.4 6 15.6 80.4 6 15.6
Median (IQR) 85 (15) 85 (15)
Mobility, n (%)
No problems 812 (71.6) 790 (71.7)
Slight problems 208 (18.3) 204 (18.5)
Some/moderate problems 79 (7.0) 77 (7.0)
Severe problems 31 (2.7) 28 (2.5)
Unable to walk about 4 (0.4) 3 (0.3)
continued on next page
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Table 1. Continued
Characteristic General population* (%) Full sample (n = 1134) Analytic sample† (n = 1102)
Self-care, n (%)
No problems 1060 (93.5) 1032 (93.6)
Slight problems 42 (3.7) 41 (3.7)
Some/moderate problems 25 (2.2) 25 (2.3)
Severe problems 5 (0.44) 3 (0.3)
Unable to wash or dress 2 (0.18) 1 (0.1)
Usual activities, n (%)
No problems 854 (75.3) 828 (75.1)
Slight problems 178 (15.7) 175 (15.9)
Some/moderate problems 80 (7.1) 79 (7.2)
Severe problems 16 (1.4) 16 (1.4)
Unable to do usual activities 6 (0.5) 4 (0.4)
Pain/discomfort, n (%)
No pain or discomfort 556 (49.0) 540 (49.0)
Slight pain or discomfort 374 (33.0) 364 (33.0)
Moderate pain or discomfort 151 (13.3) 148 (13.4)
Severe pain or discomfort 39 (3.4) 38 (3.5)
Extreme pain or discomfort 14 (1.2) 12 (1.1)
Anxiety/depression, n (%)
Not anxious or depressed 699 (61.6) 679 (61.6)
Slightly anxious or depressed 272 (24.0) 265 (24.1)
Moderately anxious or depressed 131 (11.6) 128 (11.6)
Severely anxious or depressed 24 (2.1) 23 (2.1)
Extremely anxious or depressed 8 (0.7) 7 (0.6)
cTTO indicates composite time trade-off; DCE, discrete choice experiment; IQR, interquartile range; SD, standard deviation; VAS, visual analogue scale.
*General population estimates were based on US Census estimates (2011-2015 American Community Survey 5-y estimates) unless otherwise referenced.
†Analytic sample included respondents who provided eligible responses for the cTTO or DCE.
PREFERENCE-BASED ASSESSMENTS 937(20.414), and the smallest was usual activities level 2 (20.068).
Statistically signiﬁcant differences were observed between levels
for each of the 5 dimensions except mobility (levels 2-3), self-care
(levels 2-3), and anxiety/depression (levels 4-5).
In applying the preferred model as a scoring algorithm for EQ-
5D-5L health state utilities, an index-based summary score is
obtained by subtracting parameter estimates for each dimension
level of the health state from 1. For example, for the health state
21354, the utility would be 1 2 (0.096 1 0 1 0.101 1 0.414 1
0.299) = 0.090 (see Appendix J in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2019.02.009).
Overall mean scores generated for the EQ-5D-3L using the
Shaw et al value set, the crosswalk, and the EQ-5D-5L value set
from the present study were 0.369 6 0.225, 0.416 6 0.194, and
0.236 6 0.272, respectively.14,15 The kernel density plot shows the
distribution of EQ-5D-5L values to be unimodal and symmetric,
with a wider range of scale (20.573 to 1) than the EQ-5D-3L value
set and crosswalk (20.109 to 1) (Fig. 3). The EQ-5D-5L value set
had 624 health states that were WTD (20.0%), whereas the EQ-5D-
3L and crosswalk value sets had 10 (4.1% of 243) and 39 (1.2% of
3125) health states that were WTD, respectively.14,15 Sensitivity
analyses resulted in marginal differences in the model estimates.
No signiﬁcant interviewer effect was observed.Discussion
A US-based value set for the EQ-5D-5L was developed on the
basis of a standardized international protocol that can help inform
economic evaluations and decision making in US health systems
as well as facilitate cross-country comparisons of health prefer-
ences and cost effectiveness. The value set fulﬁlls criteria outlined
by the Second Panel of Cost-Effectiveness in Health and Medicinefor generating QALYs for the purposes of cost-utility analyses,
providing quality weights that are preference-based, interval-
scaled, and sourced from a “community-based” (societal)
sample.48
The Tobit model (model 1) based on cTTO data was selected as
the preferred model for the value set. Although there is no crite-
rion standard for modeling preference data, combining data from
different elicitation techniques such as the cTTO and DCE required
assumptions of statistical and conceptual appropriateness that
were unnecessary in this study; the Tobit model using cTTO-only
data provided a value set that fulﬁlled our criteria. In addition, we
were able to account for within-subject dependency of the ob-
servations by using a respondent-level random effect. The hybrid
model is, however, a pragmatic compromise to combine prefer-
ences from methods with different shortcomings, for example,
scale compatibility and loss aversion49 for the cTTO, attribute
nonattendance and lexicographic preferences for the DCE,50–52
and would fully use the collected preference data.
The predicted value for 55555 using the Tobit model (model 1)
was 20.573 and the mean observed cTTO value was 20.366; this
difference was due to both the extrapolation of predicted values
(ie, censoring at 21) and accounting for heteroscedasticity of the
variance. During interviews, respondents often expressed the
desire to trade beyond the cTTO value of 21; furthermore, ho-
moscedasticity of the error was rejected, indicating the presence
of heteroscedasticity. Thus, these modeling aspects should be
included in the ﬁnal value set. A similar pattern was seen in other
countries that have also used the Tobit model with censoring
at 21 and/or heteroscedasticity, which include value sets in Ger-
many53 and Indonesia.54
Although an evaluation of the implications of transitioning
from the EQ-5D-3L to the EQ-5D-5L is beyond the scope of this
study, a few differences between the US EQ-5D-3L and the US EQ-
Figure 2. Distribution of cTTO observations by (A) value and (B) health state severity. Misery score is calculated by summing the severity
levels across all 5 dimensions; for example, the misery score for health state 21354 would be 15 (21 1 1 3 1 5 1 4).
cTTO indicates composite time trade-off.
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were based on TTO tasks, the WTD elicitation tasks differed be-
tween studies (EQ-5D-3L: conventional TTO, scaled to 21 to 1
QALY scale; EQ-5D-5L: lead-time TTO).32 Furthermore, the statis-
tical models differed in speciﬁcation, that is, presence of interac-
tion terms, heteroscedasticity of variance, and censoring. The TTO
technique and modeling variations may both contribute to a
greater range of scale for the EQ-5D-5L: 20.573 to 1 (EQ-5D-5L)
and 20.109 to 1 (EQ-5D-3L).
This study has several strengths, particularly the imple-
mentation of a standardized protocol on the basis of evidence
generated by researchers in and outside the EuroQol Group.16,21The standardized protocol ensured similar data collection
methods, interviewer training, and data quality control. To tailor
the protocol and EQ-VT platform to US-speciﬁc factors, scientiﬁc
and stakeholder advisors were consulted to guide study design
and recruitment strategies and inform user uptake. Another
study recently sought to estimate preferences for EQ-5D-5L
health states for the United States55 on the basis of DCE with
duration data from a EuroQol-sponsored experimental
modeling exercise.56 It was not based on the standard protocol
and data quality control processes developed by the EuroQol
Group, and used exclusively online panel respondents, which
may have data quality and generalizability issues.57 Future
Table 2. Parameter estimates for main-effects models.
Dimension/level Model 1: cTTO (Tobit with
heteroscedasticity, censored
at 21, RE) (preferred model)
Model 2: DCE (mixed logit,
rescaled to censored cTTO
mean values)
Model 3: hybrid (Tobit with
heteroscedasticity, censored
at 21, conditional logit)
Estimate SE P value Estimate SE P value Estimate SE P value
MO2 20.096 0.015 ,.0001 20.092 0.011 ,.0001 20.077 0.009 ,.0001
MO3 20.122 0.016 ,.0001 20.090 0.015 ,.0001 20.102 0.012 ,.0001
MO4 20.237 0.018 ,.0001 20.232 0.016 ,.0001 20.247 0.012 ,.0001
MO5 20.322 0.016 ,.0001 20.331 0.021 ,.0001 20.364 0.012 ,.0001
SC2 20.089 0.014 ,.0001 20.079 0.011 ,.0001 20.068 0.009 ,.0001
SC3 20.107 0.017 ,.0001 20.071 0.013 ,.0001 20.08 0.012 ,.0001
SC4 20.220 0.018 ,.0001 20.251 0.019 ,.0001 20.225 0.012 ,.0001
SC5 20.261 0.016 ,.0001 20.299 0.023 ,.0001 20.288 0.011 ,.0001
UA2 20.068 0.015 ,.0001 20.044 0.011 ,.0001 20.051 0.009 ,.0001
UA3 20.101 0.016 ,.0001 20.055 0.013 ,.0001 20.068 0.011 ,.0001
UA4 20.255 0.013 ,.0001 20.166 0.016 ,.0001 20.205 0.012 ,.0001
UA5 20.255 0.013 ,.0001 20.207 0.016 ,.0001 20.236 0.011 ,.0001
PD2 20.060 0.013 ,.0001 20.094 0.013 ,.0001 20.065 0.008 ,.0001
PD3 20.098 0.017 ,.0001 20.151 0.017 ,.0001 20.108 0.012 ,.0001
PD4 20.318 0.015 ,.0001 20.393 0.027 ,.0001 20.367 0.013 ,.0001
PD5 20.414 0.017 ,.0001 20.399 0.026 ,.0001 20.441 0.013 ,.0001
AD2 20.057 0.014 ,.0001 20.076 0.015 ,.0001 20.057 0.008 ,.0001
AD3 20.123 0.018 ,.0001 20.150 0.018 ,.0001 20.133 0.012 ,.0001
AD4 20.299 0.016 ,.0001 20.310 0.025 ,.0001 20.329 0.012 ,.0001
AD5 20.321 0.015 ,.0001 20.369 0.027 ,.0001 20.371 0.012 ,.0001
Dimension
ranking
PD-MO-AD-SC-UA PD-AD-MO-SC-UA PD-AD-MO-SC-UA
Estimated utility values by health state
21 111
0.904 0.908 0.923
12111
0.911 0.921 0.932
11211
0.932 0.956 0.949
11121
0.940 0.906 0.935
11112
0.943 0.924 0.943
55555
20.573 20.605 20.699
No. of health states WTD, n (%) 624 (20.0) 669 (21.4) 733 (23.5)
AD indicates anxiety/depression; cTTO, composite time trade-off; DCE, discrete choice experiment; MO, mobility; PD, pain/discomfort; RE, random effects; SC, self-care;
SE, standard error; UA, usual activities; WTD, worse than dead.
PREFERENCE-BASED ASSESSMENTS 939studies comparing the scoring approaches may be inevitable,
but initial indicators such as the range of the values suggest that
the EQ-5D-5L value set in the present study has a wider range of
scale and thus may generate larger QALY gains. Furthermore, the
EuroQol Group has issued guidance on country-speciﬁc value
sets used by users for health technology assessment–related
decision making and promotes the use of value set–based data
collected using the standardized international protocol, such as
the present value set.21
This study also has several potential limitations. Alternative
model speciﬁcations were explored to only a limited extent,
because the experimental design of the EQ-VT protocol was
optimized for a main-effects model. Law et al58 explored the useof N45 terms on the cTTO data and found minimal model ﬁt
improvements with the inclusion of interaction terms, sug-
gesting that a main-effects model would be best for parsimony
and interpretation. Also, generalizability of study respondents
to the US general population may be limited in that data
collection was conducted in metropolitan areas in the summer.
Non–quota-sampled characteristics of respondents do closely
match reported estimates (Table 1), lending conﬁdence to
representativeness of the respondents. A seasonal effect has
been detected in self-reported health59; nevertheless, it is un-
clear whether stated preferences for hypothetical health states,
as in this study, are impacted by season. Quota sampling was
based on the US Census, which does not inquire about
Figure 3. Kernel density plot of US EQ-5D value sets.
EQ-5D-3L/5L indicates 3-/5-level EuroQol 5-dimensional questionnaire.
940 VALUE IN HEALTH AUGUST 2019citizenship status; thus, the quota sampling approach pertains
to US residents, not just citizens.Conclusions
A US value set for the EQ-5D-5L is an important resource to
support economic evaluations of healthcare interventions. The
wider range of scale and improved measurement properties
associated with the 5-level descriptive system, such as greater
sensitivity to changes in health status, are likely to translate into
differences in QALY calculations compared with the EQ-5D-3L14
and the crosswalk.15 In addition, use of a standard protocol in
the present study will facilitate comparisons with international
value sets for the EQ-5D-5L.21 Studies that compare the EQ-5D-5L
value set with the EQ-5D-3L value set such as Law et al58 and
other utility measures will assist in understanding the implica-
tions of this value set for estimating QALYs and the adoption of
health technology. The full value set can be retrieved by contacting
the corresponding author or the EuroQol Group.Acknowledgments
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